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Company Indianapolis, IN 46285, United States.The identiﬁcation of a novel metastasis suppressor function for the MAP Kinase Kinase 4 protein
established a role for the stress-activated kinases in regulating the growth of disseminated cancer
cells. In this review, we describe MKK4’s biological mechanism of action and how this information
is being used to guide the development of newmodels to study cancer cell dormancy and metastatic
colonization. Speciﬁcally, we describe the novel application of microvolume structures, which can
be modiﬁed to represent characteristics similar to those that cancer cells experience at metastatic
sites. Although MKK4 is currently one of many known metastasis suppressors, this ﬁeld of research
started with a single daring hypothesis, which revolutionized our understanding of metastasis, and
opened up new areas of exploration for basic research. The combination of our increasing knowl-
edge of metastasis suppressors and such novel technologies provide hope for possible clinical inter-
ventions to prevent suffering from the burden of metastatic disease.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
At the time of diagnosis, many cancer patients already have dis-
seminated cancer cells within secondary tissues far-removed from
the primary tumor [1–3]. This points to the importance of under-
standing how cancer cells, which may persist at sites for long peri-
ods of time, ultimately form clinically-signiﬁcant metastases.
Many researchers are focusing on the detection and biological sig-
niﬁcance of such disseminated cells in the clinical setting. Given
the fragmentary data on the process of secondary organ coloniza-
tion, many investigators are relegated to piecing together informa-
tion from various sources to develop working models of how
dormant cancer cells initiate growth and go onto form detectable
metastases. In recent years, discoveries from the study of metasta-
sis suppressors (i.e. genes, proteins or non-coding RNAs which spe-cal Societies. Published by Elsevier
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ch Laboratories, Eli Lilly andciﬁcally suppress metastasis formation) have yielded new insights
into molecular and cellular mechanisms controlling the process of
metastatic colonization [4–6].
Given the tremendous progress that has been made in the ﬁeld
of metastasis suppressor research it is humbling to consider that
the birth of this area of scientiﬁc endeavor hinged on a single daring
hypothesis put forth by Dr. Patricia Steeg, who was then a postdoc-
toral fellow at the National Cancer Institute [6]. Since tumorigene-
sis and metastasis are separable processes, she hypothesized that
one could identify genes that speciﬁcally suppress metastasis for-
mation without affecting tumor growth. Once identiﬁed such
metastasis suppressor genes could be used to tease out processes
that are speciﬁcally involved in metastasis formation [7]. Through
tenacious efforts, she identiﬁed and published the ﬁrst metastasis
suppressor nm23 and showed that consistent molecular events
underlying metastasis could be identiﬁed [8]. Not only did this open
the door to the molecular studies of metastasis that are common-
place today, ultimately it forced investigators to reconsider funda-
mental tenants of metastasis biology. For example, when efforts to
ﬁnd metastasis suppressors were initiated, it was expected that
their utility would be in predicting disease outcome. This is be-
cause escape of cells from the primary tumor was considered to
be the rate-limiting step in metastasis formation. It logically fol-
lowed that metastasis suppressors would block escape of cells
from the primary tumor. However, robust in vivo studies showedB.V. Open access under CC BY-NC-ND license.
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cells at secondary sites [9–12]. Interestingly, other investigators,
working on completely different questions, also identiﬁed meta-
static colonization as a rate-limiting step in metastasis formation
[13,14].
As evidenced by this mini-review series, there is now a rich and
vibrant literature on metastasis suppressors. As such, there are
many excellent scholarly reviews and publications that provide de-
tailed descriptions of molecular, biochemical, and cellular effects
and functions of speciﬁc metastasis suppressors [6,15,16]. Thus,
we will take a somewhat different approach in our discussion of
the identiﬁcation of a novel metastasis suppressor function for
the stress-activated protein kinase c-Jun NH2-terminal kinase
(JNK) kinase 1/mitogen-activated protein kinase (MAPK) kinase 4
(hereafter referred to as MKK4). The following sections will present
a concise overview of the discovery of MKK4’s metastasis suppres-
sor activity, studies to discern its biological mechanism of action,
and new engineering approaches that may be used to develop
models of cancer cell dormancy and metastatic colonization.
2. MKK4 – A stress-activated signaling kinase that is involved in
growth of cancer cells at secondary sites
Our laboratory identiﬁed MKK4 as a prostate cancer metastasis
suppressor in 1999 [17] and subsequently as an ovarian cancer
metastasis suppressor in 2002 [18]. MKK4 is a MAP kinase within
the classically deﬁned stress-activated protein kinase (SAPK) cas-
cade. To date, three MAP kinase modules have been well character-
ized: extracellular signal-regulated protein kinase (ERK), c-Jun
NH2-terminal protein kinase (JNK), and p38 [19]. The JNK and
p38 pathways are generally activated by stress stimuli such as
cytokines, pH changes, and ionizing radiation [19]. MKK4 is a
dual-speciﬁcity kinase, which in response to extracellular stimuli,
can become activated and in turn can phosphorylate and activate
the JNK and p38 MAPKs. This distinguishes MKK4 from MKK7,
which can only phosphorylate JNK. It also differs from MKK3 and
MKK6, which can only phosphorylate p38. The signaling events
and biological outcomes of activation of MKK4 within the SAPK
cascade are the subject of several excellent reviews [20–24]. Thus
we will focus on our efforts to determine the mechanism by which
MKK4 impairs metastasis formation.
Ectopic expression of MKK4 decreased the number of sponta-
neous AT6.1 rat prostate cancer metastases by P90% (P < 0.0001)
without affecting primary tumor formation [12,17]. Spontaneous
metastatic ability is deﬁned as the ability of the cells to dissem-
inate from the primary tumor and form overt metastases at the
secondary site (lung). The metastasis suppressors identiﬁed prior
to MKK4 (Nm23, Kai1, Brms1, and Kiss1) were all novel proteins.
In contrast, MKK4’s known functions in the SAPK pathway pro-
vided us with the huge advantage of information and tools that
enabled mechanism-based studies. Based upon its known bio-
chemical function, we hypothesized that MKK4’s metastasis sup-
pressor activity would be dependent on its kinase activity.
Studies using a kinase-inactive mutant showed that this is in-
deed the case [10,12]. At this point much of our data ﬁt the lim-
ited knowledge of in vivo effects of metastasis suppressors and
how MKK4 should function. One curious observation, however,
was the presence of microscopic lesions in the lungs of animals
bearing tumors, which expressed ectopic MKK4 [17,25]. This
suggested that MKK4 did not block the escape of cancer cells
from the primary tumor, but rather impaired the growth of cells
after they had lodged in the lung (the secondary site for metas-
tasis formation in this model system). Subsequent quantitative
studies indicated that MKK4 did not affect the number of cells
lodging within the secondary site [12,26,27].Our ﬁndings, which countered the prevailing view that escape
from the primary tumor was the rate-limiting step in metastasis
formation, emerged at a time when data from the laboratories of
Dr. Ann Chambers, Dr. Dan Welch, Dr. Lilly Ossowski, and others
also suggested ‘‘growth control’’ at the metastatic site could be a
rate-limiting step for metastasis formation [14,28–32]. As we con-
sidered these apparently contradictory data, we recalled the wis-
dom of Dr. Donald S. Coffey, ‘‘If two good investigators disagree
and a paradox seems to exist, both of their data are probably cor-
rect, and we just need a new explanation to encompass both obser-
vations’’ [33]. To this end, members of our team set forth to
develop daring hypotheses to address such paradoxes and or crit-
ical gaps in knowledge. The ﬁrst such hypothesis was proposed and
tested by Dr. Donald Vander Griend. He proposed the loneliness
hypothesis, which compared cancer cells leaving from a primary tu-
mor to explorers colonizing distant lands. He suggested that as
lone disseminated cells or cells within small aggregates, these can-
cer cells would ‘‘miss the environment of their homeland (primary
tumor)’’ and respond to physical and chemical stresses in their
microenvironment. With respect to MKK4, he speculated that early
in the process of colonization, the stress experienced by the rela-
tively small number of ‘‘lonely’’ cells that lodged in the potentially
hostile environment of the lung would activate ectopic MKK4
(which lies within the SAPK cascade) resulting in impaired metas-
tasis formation. To test this, in vitro kinase assays were used to
measure the activity of HA-tagged MKK4 protein isolated from dis-
seminated cancer cells within the lung. The full details of this study
are presented in Ref. [12]. In sum, these studies showed that HA-
MKK4 immunoprecipitated from cells within the lung could phos-
phorylate a puriﬁed JNK substrate, while protein similarly isolated
from primary tumors could not [12] (Fig. 1). These data are consis-
tent with ﬁndings that ectopically expressed MKK4 suppresses
metastasis formation without affecting 1 tumor growth.
Despite the compelling data, the possibility remained that
MKK4 could be activated during the process of dissemination from
the primary tumor. Szmulewitz et al. designed a clever set of
experiments to rule out this possibility [27]. First, using quantita-
tive PCR they showed that in standard spontaneous metastasis as-
says using AT6.1 cells, there are approximately 1  104 cells per
lung at early timepoints during metastatic colonization. Using this
baseline information they showed that ectopically expressed
MKK4 suppressed metastasis formation of three highly malignant
rat prostate cancer cell lines (i.e. AT6.1, AT3.1 and Mat-Lu) in
experimental metastasis assays (i.e. cells injected via tail vein). In-
deed, the extent and duration of metastasis suppression and in-
creased survival of animals in these experimental metastasis
assays paralleled that seen in previous work using spontaneous as-
says [12]. As indicated in Fig. 1, whether cells are delivered to the
secondary site by the primary tumor (spontaneous metastasis as-
say) or delivered directly (experimental metastasis assay) MKK4
becomes activated in cells lodged within the target organ and con-
trols subsequent steps in the colonization process.
3. MKK4-mediate suppression is due to induction of a reversible
cell cycle arrest of cells lodged at secondary sites
Various studies support a role for MKK4 dysregulation in clini-
cal disease [18,19,34–43]. In ovarian cancer, the relationship be-
tween its expression and metastasis formation has been
particularly informative. MKK4 protein levels were signiﬁcantly
decreased in metastases as compared to normal ovarian surface
epithelium [18]. Proﬁling studies identiﬁed high MKK4 expression
as a signiﬁcant predictor of improved response to surgical cytore-
duction [44]. In vivo functional studies used SKOV3ip.1 human
ovarian cancer cells, which form metastatic deposits of a serous
EXPERIMENTAL 
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Fig. 1. Summary of MKK4’s activity and biological effect during metastatic colonization.
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metastases on the omentum, liver, and bowel [32]. SKOV3ip.1 cells
have low endogenous levels of MKK4 but retain physiologic levels
of other components of its signaling cascade [18]. Ectopic MKK4
decreased the number of SKOV3ip.1 metastases by 88%
(P < 0.0001) and increased the animal lifespan by 70% (Wilcoxon,
P = 0.0045) [18]. Its metastasis suppressor function is kinase-
dependent and studies showed that selective activation of p38 re-
duced SKOV3ip.1 metastasis formation by 70% (P = 0.0082) [10].
These data further deﬁned MKK4’s metastasis suppressor activity
and prompted the question – What is the biological mechanism of
MKK4-mediated metastasis suppression?
In both spontaneous and experimental metastasis assays using
prostate cancer cell lines, MKK4-mediated suppression is transient,
with eventual outgrowth of MKK4-expressing cells [12,27]. Lotan
et al. similarly found that found that mice injected with MKK4-
expressing SKOV3ip.1 ovarian cancer cells eventually develop mac-
roscopic metastases and succumb to their disease burden [26]. This
raised an interesting question of whether bypass of metastasis sup-
pression was due to selection of cells, which had permanent alter-
ations in MKK4 or its signaling cascade, or alternatively, the
population had undergone an adaptive process, which rendered
MKK4 no longer active. To distinguish between these possibilities
a mathematical analysis of the rate of accumulation of overt exper-
imental metastases in the SKOV3ip.1 model, as well as the extent
and duration of suppression by MKK4 was conducted. Biological
and molecular assessments showed that outgrowth of MKK4-
expressing SKOV3ip.1 cells was due to a population-wide adapta-
tion and not permanent genetic alterations that impaired MKK4-
signaling [26]. Further support for these ﬁndings was provided
by the study of overt implants arising from HA-MKK4-expressing
SKOV3ip.1 cells. Molecular analyses showed that these metastases
continue to express HA-MKK4, indicating that no selection oc-
curred. Additional studies showed that metastasis-derived cell
lines retained biochemically functional MKK4 and were still sup-
pressed in their ability to form overt experimental metastases
when reinjected into naïve mice [26]. Subsequent work by Szmule-
witz et al. showed similar results for MKK4-expressing AT6.1 pros-
tate cancer cells. In further support of the loneliness hypothesis,
using in vitro kinase assays they also showed that MKK4-puriﬁed
frommacroscopic metastases was not activated [27] (Fig. 1). Taken
together, accumulated data from the prostate cancer and ovarian
cancer model systems showed that ectopically expressed MKK4
did not affect the number of cells lodging at secondary sites, but
rather caused a reversible impairment in the progressive growth
of cells.
In most cases the formation, or growth, of overt metastases is
the net result of both apoptosis and cell proliferation. Because of
MKK4’s role in the SAPK pathway and the association of this path-
way with induction of apoptosis, conventional wisdom dictated
that MKK4-mediated metastasis suppression was due to increased
apoptosis of disseminated cancer cells. Based upon evaluation of
the histopathology of the lesions, Lotan et al. put forth the daringhypothesis that MKK4 was actually affecting proliferation [26].
To test this, MKK4-expressing SKOV3ip.1 omental lesions and
paired vector-only controls were assessed molecularly for apopto-
sis early in the time course of in vivo metastatic colonization. These
data found only rare apoptotic cells in both groups. In contrast,
analysis of proliferation revealed that BrdU incorporation was sig-
niﬁcantly decreased in MKK4-expressing cells as compared to vec-
tor controls (e.g. average of 6% versus 19% positive cells,
P < 0.0001). Similar results were found using phospho-histone H3
staining. The decrease in both BrdU incorporation and phospho-
histone H3-positive cells in MKK4-expressing microscopic lesions
suggested that fewer cells were traversing S phase and subse-
quently M phase compared with controls. This ﬁnding, coupled
with the fact that these cells eventually proliferate to form macro-
scopic implants, is consistent with a reversible cell cycle arrest
(Fig. 1).
To further examine the possibility of a reversible cell cycle ar-
rest, Lotan et al. evaluated the expression of cell cycle inhibitory
proteins, potentially acting in the MKK4-expressing microscopic
lesions. SKOV3 cells are known to be null for a variety of cell cycle
inhibitors including p53 and p16 [26,45–47]; thus, protein expres-
sion of p21(Waf1/Cip1) was quantiﬁed in MKK4-expressing micro-
scopic metastases. p16 immunostaining provided a negative
control for this series of experiments. This approach revealed that
p21 expression was increased nearly 10-fold in HA-MKK4-express-
ing microscopic lesions compared with vector-only controls (aver-
age of 9% versus 1%, P < 0.0001). Taken together with the decreased
BrdU incorporation and phospho-histone H3 staining, these data
were consistent with impaired cellular proliferation [26]. To fur-
ther test this observation, Szmulewitz et al. dissociated lungs from
mice with disseminated AT6.1 cells and used ﬂow cytometry to
analyze the cell cycle distribution of the disseminated cells. They
showed that MKK4 over-expressing cells have a signiﬁcant in-
crease in G1-phase cells (P = 0.024), with a corresponding decrease
in S-phase cells (P = 0.036), when compared to a vector-only
expressing control [27]. Taken together, results from both the ovar-
ian and prostate cancer model systems indicate that activation of
MKK4 in disseminated cells causes reversible alterations in the cell
cycle which are linked to impaired proliferation and inhibition of
metastatic colonization.
4. Considering the role of the microenvironment in the tissue-
speciﬁc activation of MKK4
The two key aspects of the loneliness hypothesis are the num-
ber of disseminated cancer cells and the environment of the sec-
ondary site. Our initial studies of MKK4 focused on the effect of
its activation on cancer cells, but what is the speciﬁc microenviron-
ment that the cells see? We reasoned that in order to fully under-
stand how MKK4 functions as a metastasis suppressor, we needed
to investigate the neighbors and the neighborhood in which dis-
seminated cancer cells must survive and adapt to in order to estab-
lish themselves. To begin this effort, we chose to focus on the
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cancer, as well as experimental models, the omentum is the pri-
mary site of metastasis formation [48,49]. The human omentum
is a peritoneal fold composed of layers of mesothelial cells that
envelope adipose tissue [50]. This highly vascularized organ is a
storage site for lipids, a regulator of peritoneal ﬂuid transit, and a
reservoir for immune cells in the peritoneal cavity [50–52]. It ex-
tends from the stomach and blankets most abdominal organs,
which may partly explain its susceptibility to colonization by ovar-
ian and peritoneal cancer cells within ascites [53,54]. Despite its
clinical importance, the omentum remains an understudied organ,
and fundamental aspects of it structure, function, and composition
have not been well-integrated into current models of ovarian can-
cer metastasis formation. This could be of crucial importance since
dissemination of cells to secondary sites often occurs early in the
process of tumor progression. Indeed Klein has proposed that
metastases and primary tumors undergo parallel progression [1].
If this is true, it implies that disseminated cells evolve in response
to the conditions of the microenvironment of the secondary site.
In their studies, Lotan et al. found that during metastatic coloni-
zation SKOV3ip.1 ovarian cancer cells were invariably found in
association with immune aggregates within the omentum [26].
This observation prompted a rigorous evaluation of the literature.
We learned that omenta from a wide variety of animals contain
aggregates of immune cells which were ﬁrst described by von Rec-
klinghausen in 1863 [55] and termed milky spots by Ranvier in
1875 [55] (Fig. 2A). As indicated in Fig. 2B, the immune aggregates
that deﬁne milky spots overlie dense vasculature and are sur-
rounded by adipocytes. These structures are specialized to enable
mobilization of immune cells for migration into the peritoneal cav-
ity. Scanning electron micrographs indicate that the mesothelial
layer over milky spots is discontinuous with stomata that may pro-
vide openings for transit of cells [56]. In agreement with our obser-
vations, two recent papers showed the preferential localization of
cancer cells to milky spots on the omentum [53,57]. In our previ-
ous studies we have found that SKOV3ip.1 cells rapidly localize
to milky spots and initially are interspersed throughout the im-
mune cells of the milky spot (Fig. 2C). In later time points, cancer
cells exist in discrete islands of cells surrounded by immune cells
(Fig. 2D). The mechanisms and timing of this apparent transitionKey: Panel B mesothelial cell layer adipocytes
basement membrane
immune cells
vasculature
extracellular matrix
Fig. 2. Cancer cells colonize milky spots during metastatic colonization of the
omentum. (A) H and E of omentum showing intense purple staining of immune
aggregates referred to a milky spots (designated MS); (B) schematic of omentum
showing characteristic features of a milky spot including immune cells, overlying
stomata in the mesothelial layer, vasculature, and surrounding adipocytes; (C)
immunohistochemical detection of cancer cells within the milky spot via cytoker-
atin staining (detected as discrete brown-staining cells) 6 h after intraperitoneal
injection; (D) H and E staining of omentum showing the presence of discrete islands
of cancer cells within milky spots within the 10 days after intraperitoneal injection.
Panels (A) and (C) are reproduced from Khan et al. [55], while panel (D) is
reproduced from Lotan et al. [26].are currently under investigation. In our view, the omental meta-
static colonization system seems to be amenable to studies of
interactions between cancer cells and host cells during this com-
plex process. Further, our mechanistic knowledge of how MKK4
disrupts metastatic colonization can be used to develop in vitro
models that enable dissection of physical and biochemical signals
important to survival and progressive growth of cells lodged at sec-
ondary sites (such as the omentum).
5. Developing models to study metastatic colonization
Identifying speciﬁc factors that regulate the biological fate of
disseminated cells holds great promise for the development of
adjuvant therapies to control minimal residual disease. A search
of electronic databases shows that many investigators are focusing
on this problem, yet much work remains to be done. For the most
part, in vitro systems are designed to model cellular behaviors on a
large scale. That is, large numbers of cancer cells interacting with
large amounts of host tissue, cells, matrix, etc. [58–63]. Such strat-
egies are based on the combination of the technologies generally
available to cancer biologists and longstanding approaches to the
study of biological problems. In some cases such approaches do
yield data that can be translated back into animal models,
although, based upon clinical and experimental ﬁndings often
these systems do not mimic the physical constraints that lone dis-
seminated cells (or small numbers of cells) likely experience as
they colonize target tissues. This potentially has critical ramiﬁca-
tions in understanding cancer progression within secondary tis-
sues, as the behavior of cells can vary widely depending, for
example, on their access to nutrients, diffusible signals, cell-adhe-
sion opportunities, and other factors that depend on population
size and the volume and geometry of microscopic niches. Recent
technological advances are enabling the construction of micro-
structures that can recapitulate key attributes of microscopic
niches in tissues, providing the capacity to tune the size, mass
transport properties, chemistry, and elasticity of micrometer-scale
enclosures capable of sequestering small numbers of cells. Our lab-
oratories are now pursuing the daring hypothesis that such micro-
structures will offer unique opportunities to model the earliest
steps of metastatic colonization and cancer-cell dormancy.
Connell et al. recently reported using such microstructures to
study population-dependent changes in cellular behavior, probing
the capacity of pathogenic bacteria to engage in quorum sensing
and acquire bioﬁlm-like antibiotic resistance [64]. Methods were
developed for fabricating three-dimensional (3D) picoliter-scale
microcavities out of photo-cross-linked bovine serum albumin
(BSA) walls using a mask-based multiphoton lithography tech-
nique [64]. Microcavities could be fabricated with arbitrary size
and shape, and typically were created with a funneled entry-way
to help guide ﬂagellated (i.e., swimming) cells from the bulk med-
ium into the lumen of a cavity. By increasing the bath temperature
from ambient to physiologic levels, the crosslinked protein walls
expanded, thus causing entry-ways to pinch closed and retain cells
within the trap. Once conﬁned, cells could be tracked optically for
periods of several hours. The protein-based walls enabled facile
mass transport of nutrients, gases, and waste products, allowing
trapped cells to divide at rates indistinguishable from those in bulk
medium (a fundamental hallmark of physiologic normalcy). Initial
results revealed that in populations of a few thousand cells, quo-
rum sensing in Pseudomonas aeruginosawas modulated by popula-
tion number and by the ﬂow rate of external medium at constant
bacterial densities. More surprisingly, trapped cells were observed
to become resistant to gentamicin, a common aminoglycoside anti-
biotic, in populations as small as a few hundred cells. We believe
these initial studies portend a much broader utility for protein-
Fig. 3. Protein-based microcavities offer a versatile platform for characterizing the behavior of small cellular populations. Clusters of cells retained within microcavities can
be exposed to deﬁned chemotactic (A) and haptotactic (B) agents, providing a means to systematically evaluate cellular responses to spatially-deﬁned, competing stimuli.
Entry-ways in (A) and (B) are shown in an open state, but can be designed to close under certain environmental conditions [64]. In addition, this approach provides
possibilities for evaluating the relative efﬁcacy of diffusible signals generated by different populations of cells. For example, panel (C) shows four distinct small cellular
populations, each of which release potentially different types and/or quantities of chemotactic agents. Because microcavity walls are porous to these signals, the relative
ability of each population to effect clustering of a ﬁfth cell type could be evaluated in a competitive format. For presentation purposes, microcavities in (A), (B), and (C) all are
shown with thin, nearly transparent roofs.
M.T. Knopeke et al. / FEBS Letters 585 (2011) 3159–3165 3163based microstructures in studying the population-dependent
behavior of many cell types, including metastatic cancer cells, in
well-deﬁned microenvironments. This notion is supported by re-
cent reports which make strong connections between societal
behaviors in bacteria and those of cancer cells [65–67]. One chal-
lenge in extending this method to non-swimming cells is micro-
cavity loading. A number of alternate strategies may be useful for
introducing mammalian cells into microcavities, including optical
trapping, a method used successfully for loading immotile bacteria,
microinjection, and reliance on random or guided (chemotactic or
haptotactic) motility of adherent cells.
In addition to offering a potential means to isolate small num-
bers of cancer cells for study within microscopic cavities of deﬁned
size and shape, this technology could provide vital opportunities
for manipulating attributes of protein walls to model features of
tissue microenvironments. For example, movement of small mole-
cules (such as ﬂuorescently labeled antibiotics) across the BSA
walls can be rapid, with microcavity concentrations reaching
external levels within seconds (Fig. 3A) [64]. Diffusion rates of lar-
ger molecules, such as cytokines, will likely be smaller, although in
preliminary studies a variety of molecules ranging up to tens of
kilodaltons have been observed to efﬁciently permeate into
photo-cross-linked BSA. As a result, it should be possible to direct
key signaling molecules into the traps at deﬁned times, allowing
the impact of these species on small populations of cancer cells
to be studied under well-deﬁned conditions. In addition, it may
be feasible to collect the media immediately surrounding a trap
to analyze cytokines that have diffused from conﬁned cancer cells
and across trap walls. With regard to the ovarian cancer–milky
spot interactions, such structures would be applied to testing the
effect of speciﬁc candidate chemoattractants which may prompt
the cancer cells to invade milky spot structures.
Another feature of such structures is the ability to modify the
protein walls with biotinylated molecules of interest (Fig. 2B). Such
functionalization can be accomplished by constructing walls from
photo-cross-linked avidin, which has been shown to retain sub-
stantial biotin-binding capacity, or by photocrosslinking biotinyla-
ted BSA and decorating walls with avidin after they are fabricated
[64]. Such modiﬁcations to the interior walls would allow one to
observe the behavior of cells in response to speciﬁc chemical char-
acteristics, depending on the design of the experiment. For exam-
ple, if we consider the ovarian cancer metastatic colonization
model, we could envision decorating the walls of the structure
with candidate effector molecules and examine motility or prolif-
erative responses of cancer cells placed within the structure. Given
the composition of milky spots we suspect that such effectors
could be macrophage, adipocyte, or endothelial cell derived factors.Moreover, use of mask-based multiphoton lithography enables
intricate 3D structures to be rapidly designed and prototyped
[68,69]. This allows experimenters, for example, to iteratively eval-
uate networks of chambers of differing connectivities, with or
without openings to the surrounding environment. In one possible
conﬁguration (Fig. 3C), multi-chamber microcavities could be de-
signed to house multiple types of small cellular populations, such
as adipocytes, macrophages, endothelial cells, etc. where chemo-
tactic agents released by the populations would be allowed to
compete against one another. A given set of well-deﬁned condi-
tions speciﬁed by a researcher (e.g., cell number, cell density) could
be evaluated to determine relative chemotactic efﬁcacy. In the
example shown, chemotaxis induced by red cells dominate, either
as a result of greater release levels, greater efﬁcacy per molecule, or
the metabolic state of the responding cells (here, the tan cells in
the larger corral).
As we are at the infancy of the research using this technology, it
is important to keep in mind that the current technology must be
adapted for use in building mammalian models. Thus, it is of par-
ticular importance to use well-characterized systems with detailed
information on their in vivo biology to optimize these models. We
believe that the MKK4 metastasis suppressor system, as well as
those of other metastasis suppressors or matched metastatic and
non-metastatic variants is ideally suited for model optimization.
In this application, metastasis suppressors would be used to iden-
tify speciﬁc genes, molecules, or cellular interactions which are re-
quired for efﬁcient metastatic colonization. They could also be
used to test the ﬁdelity of the model during development. For
example, if the in vitro model adequately recapitulates the impor-
tant features of the milky spot microenvironment, the SKOV3ip.1-
MKK4 cells should undergo reversible growth arrest when placed
in it.
In addition to the need for optimization of biology, there are
several other challenges that we are currently addressing. The
ﬁrst is an issue of scale. To date, the BSA microcavities have only
been used on the scale of 2–6 pl, with dimensions suitable for
the growth and proliferation of up to thousands of bacterial-
sized cells. Although it is relatively straightforward to increase
the lateral dimensions of microcavities (initially, 20 lm), a
greater challenge is extending the z-axis (i.e., height) of the
structure to house multiple layers of cancer cells. While pro-
tein-walled microcavities are probably limited to heights of a
few tens of microns when fabricated at the highest possible res-
olution, this likely can be extended several fold via relatively
modest sacriﬁces in minimum feature sizes. Consequently, it
should be possible to create microcavities that can accommodate
a thickness of at least 10–15 cells.
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Metastasis suppressors have provided new insights into fun-
damental aspects of the biology of metastasis. We have now en-
tered a phase where metastasis suppressors can be used as tools
for discovery and targets for therapy. With regard to the former,
we propose using MKK4 to disrupt cancer cell–microenviron-
ment interactions to determine what is necessary and sufﬁcient
for metastatic colonization of speciﬁc target organs. We also are
using this knowledge to develop models to study the early steps
of dormancy and metastatic colonization. We believe that the
development of such models is crucial, as trying to predict accu-
rately where a particular metastatic cancer cell will lodge and
whether or not that speciﬁc cell will survive and continue to
proliferate is akin to playing a game of ‘‘whack-a-mole’’ blind-
folded on a football ﬁeld. For example, when considering ovarian
cancer, we know that dormant metastatic cells are likely to
lodge ‘‘on the football ﬁeld’’ of the omentum, but we do not
know the structural and/or biochemical features of the microen-
vironment that predict where the cells will lodge and when (or
if) the cells will survive and ultimately grow. The ability to de-
sign and manipulate a microenvironment to test the functional
role of speciﬁc molecules on the behavior of cancer cells would
be a watershed. It is hoped that by sharing the approaches that
we have used to generate our published ﬁndings, as well as our
more speculative ongoing efforts toward model development, we
can encourage others to investigate metastatic colonization as a
crucial and understudied aspect of metastasis whose time has
come.
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